Reimbursement

Top five articles of the week from Specialty Pharmacy Times.

Optimized program can boost adherence and improve reporting capabilities to manufacturers.

Deborah Michaelson, MS, RPh, vice president of Operations at Ardon Health, discusses how pharmacies can help patients overcome the cost of high co-pays to maintain specialty drug adherence.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses the impact of prior authorizations on specialty pharmacy.

Grant E. Knowles, PharmD, discusses how the projected growth in specialty drug spending may change the patient experience in the years ahead.

Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity in RA.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how to optimize a drug adherence program in specialty pharmacy.

The rheumatoid arthritis (RA) drug market is projected to reach approximately $28.5 billion by 2025.

Eric Peacock, co-founder and CEO of MyHealthTeams, discusses the importance of specialty pharmacies collaborating with patients in their care.

Marc O'Connor, COO and Chief Strategy Officer at Curant Health, discusses how specialty pharmacy can help patients manage high out of pocket costs for specialty drugs.

Pharmacists can address barriers to treatment, engage with patients, and advocate for change at the community and federal levels.

Top five most popular articles this week on Specialty Pharmacy Times.

Grant E. Knowles, PharmD, vice president of Business Development at Ardon Health, discusses the potential impact of value-based care on specialty pharmacy.

Monthly and annual spending limits would likely benefit Part D enrollees.

Policies targeting both physicians and hospitals could reduce wasteful health care spending.

Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses whether increased competition for specialty drugs can lower costs.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses methods pharmacists can employ to maintain adherence.

Daniel P. Kus, BS Pharm, RPh, vice president, Pharmacy Advantage, discusses key quality measures that define successful specialty pharmacies.

Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.

The Specialty Pharmacy Patient Choice Award was created by Zitter Health Insights and Specialty Pharmacy Times to honor specialty pharmacies and their commitment to patients.

Mark A. Vineis, vice president of specialty pharmacy at Cardinal Health, discusses the elements of a successful therapy management program in specialty pharmacy.

Marc O'Connor, COO and chief strategy officer for Curant Health, discusses how specialty pharmacies can demonstrate value as the use of value-based care designs increase.

Deborah Michaelson, MS, RPh, discusses various challenges that accompany patient support in the long-term care setting.

Grant E. Knowles, PharmD, vice president of Business Development at Ardon Health, discusses how specialty pharmacies can help patients access high cost specialty drugs.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses how collaborative care programs among providers can benefit patients undergoing treatment.

The Specialty Pharmacy Patient Choice Award was created by Zitter Health Insights and Specialty Pharmacy Times* to honor specialty pharmacies and their commitment to patients.

Top news of the week from Specialty Pharmacy Times.

Specialty pharmacies that offer effective medication therapy management and support are best suited to serve as arbiters of the next generation of value-based contracts.

Specialty pharmacies will need to carefully consider the effect of the final rule regarding Anti-Kickback Statute safe harbors and Civil Monetary Penalty Law exceptions on their existing patient benefit programs.